Real-time enrollment status for this primary hyperoxaluria type 1 clinical trial
Current Status
Recruiting
Checked: July 18, 2026 at 5:38 PM UTC
| NCT Number | NCT04580420 |
| Recruiting Status | Recruiting |
| Condition | Primary Hyperoxaluria Type 1 |
| Phase | PHASE2 |
| Target Enrollment | 28 participants |
| Active Locations | 4 sites in the US |
| Sponsor | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company |
| Last Updated on CT.gov | December 24, 2025 (Dec 24, 2025) |
As of July 18, 2026: Clinical trial NCT04580420 is currently recruiting participants. This phase2 study for primary hyperoxaluria type 1 is actively seeking new participants at 4 locations across the United States. The study is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT04580420 is actively recruiting participants as of July 18, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 4 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT04580420 was last updated Dec 24, 2025 (December 24, 2025). HelloStudys verifies this status automatically.